ArticleScientific reports2026
HMGA2 identified via m6A-senescence multi-omics in laryngeal squamous cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
N6-methyladenosine (m6A) modification and cellular senescence have been individually implicated in tumor biology, but the landscape of m6A-related senescence genes in laryngeal squamous cell carcinoma (LSCC) remains underexplored. In this study, we conducted an integrated multi-omics analysis combining bulk and single-cell transcriptomics, somatic mutation and copy number variation data, and proteomics to explore the clinical and molecular impacts of m6A-related senescence. We identified 93 putative m6A-related senescence genes with prognostic value, defining molecular subtypes with distinct immune features, survival outcomes, and pathway activities. Further stratification using differentially expressed genes revealed additional heterogeneity, and a derived m6A-related senescence score (m6ASenScore) showed robust associations with prognosis and mutation burden. Single-cell analysis uncovered malignant epithelial subpopulations with subtype-specific metabolic and inflammatory profiles. Among five core candidate genes, HMGA2 was found to be significantly upregulated at the protein level. Functional experiments in LSCC cell lines showed that reducing HMGA2 levels inhibited cell growth, invasion, and migration. This study provides a comprehensive characterization of m6A-related senescence signatures and highlights HMGA2 as a potential therapeutic target in LSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.